These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1782089)

  • 21. High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: a dose-finding study.
    Nagel GA; Beyer JH; Holtkamp W; Emrich D; Kneba M; Luig H; Marschner N; Rauschning W; Unger C; Wander HE
    Onkologie; 1988 Dec; 11(6):287-8. PubMed ID: 3071764
    [No Abstract]   [Full Text] [Related]  

  • 22. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.
    Therasse P; Mauriac L; Welnicka-Jaskiewicz M; Bruning P; Cufer T; Bonnefoi H; Tomiak E; Pritchard KI; Hamilton A; Piccart MJ;
    J Clin Oncol; 2003 Mar; 21(5):843-50. PubMed ID: 12610183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer.
    Aguiar Bujanda D; Bohn Sarmiento U; Cabrera Suárez MA; Pavcovich Ruiz M; Limeres González MA; Aguiar Morales J
    J Cancer Res Clin Oncol; 2006 May; 132(5):332-8. PubMed ID: 16435143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer.
    Eisen T; Smith IE; Johnston S; Ellis PA; Prendiville J; Seymour MT; Walsh G; Ashley S
    J Clin Oncol; 1998 Apr; 16(4):1350-7. PubMed ID: 9552036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial.
    Marschner N; Kreienberg R; Souchon R; Räth U; Eggeling B; Voigtmann R; Ruffert K; Schütte M; Ammon A; Kesztyüs T
    Semin Oncol; 1994 Feb; 21(1 Suppl 1):10-6. PubMed ID: 8153652
    [No Abstract]   [Full Text] [Related]  

  • 26. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
    J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer.
    Lopez M; Papaldo P; Di Lauro L; Vici P; Carpano S; Conti EM
    Oncology; 1989; 46(1):1-5. PubMed ID: 2915887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of epirubicin and cyclophosphamide followed by weekly paclitaxel with or without trastuzumab as primary systemic therapy in locally advanced breast cancer.
    Shimizu T; Hirano A; Kamimura M; Ogura K; Kim N; Watanabe O; Kinoshita J; Kimura K; Ogawa K; Fujibayashi M
    Anticancer Res; 2010 Nov; 30(11):4665-71. PubMed ID: 21115921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer.
    Gurney H; Harnett P; Stuart-Harris R; Kefford R
    Eur J Cancer; 1995 Oct; 31A(11):1773-7. PubMed ID: 8541098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer.
    Levine MN; Bramwell V; Pritchard K; Perrault D; Findlay B; Abu-Zahra H; Warr D; Arnold A; Skillings J
    Eur J Cancer; 1992; 29A(1):37-43. PubMed ID: 1445744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.
    Piccart MJ; Di Leo A; Beauduin M; Vindevoghel A; Michel J; Focan C; Tagnon A; Ries F; Gobert P; Finet C; Closon-Dejardin MT; Dufrane JP; Kerger J; Liebens F; Beauvois S; Bartholomeus S; Dolci S; Lobelle JP; Paesmans M; Nogaret JM
    J Clin Oncol; 2001 Jun; 19(12):3103-10. PubMed ID: 11408507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer.
    Rischin D; Bishop JF; Olver IN; Laidlaw CR; Zimet A; Jeal P; Dipell JF
    Am J Clin Oncol; 1992 Oct; 15(5):392-4. PubMed ID: 1524039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
    de Azambuja E; Ameye L; Diaz M; Vandenbossche S; Aftimos P; Bejarano Hernández S; Shih-Li C; Delhaye F; Focan C; Cornez N; Vindevoghel A; Beauduin M; Lemort M; Paesmans M; Suter T; Piccart-Gebhart M
    Eur J Cancer; 2015 Nov; 51(17):2517-24. PubMed ID: 26321502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Objective response to epirubicin and lonidamine. A case of advanced thymoma previously treated with the ADOC scheme and unresponsive to paclitaxel plus cyclophosphamide.
    Berruti A; Tampellini M; Gorzegno G; Dogliotti L
    Chest; 1997 May; 111(5):1473-4. PubMed ID: 9149629
    [No Abstract]   [Full Text] [Related]  

  • 36. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
    Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
    Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
    Untch M; Muscholl M; Tjulandin S; Jonat W; Meerpohl HG; Lichinitser M; Manikhas AG; Coumbos A; Kreienberg R; du Bois A; Harbeck N; Jackisch C; Müller V; Pauschinger M; Thomssen C; Lehle M; Catalani O; Lück HJ
    J Clin Oncol; 2010 Mar; 28(9):1473-80. PubMed ID: 20177030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second and third line chemotherapy in advanced breast cancer.
    Alexopoulos A; Rigatos G; Stavrinidis E; Stavrakakis J; Scartsilas C; Papacharalambous A
    J Chemother; 1989 Jul; 1(4 Suppl):1189-90. PubMed ID: 16312828
    [No Abstract]   [Full Text] [Related]  

  • 39. An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.
    Bonnefoi H; Biganzoli L; Mauriac L; Cufer T; Schaefer P; Atalay G; Piccart M
    Eur J Cancer; 2003 Jun; 39(9):1277-83. PubMed ID: 12763217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
    Vogt U; Bielawski KP; Bosse U; Schlotter CM
    Oncol Rep; 2004 Nov; 12(5):1109-14. PubMed ID: 15492801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.